offline
RE: Vaxart Inc.
| 13.11.2020, 15:43 (Dieser Beitrag wurde zuletzt bearbeitet: 13.11.2020, 15:44 von boersenkater.)
Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate
The tiny biotech's COVID-19 vaccine has generated excitement because it's a pill instead of a shot, which gives it a number of important advantages.
Nov 12, 2020 at 12:47PM
Vaxart (NASDAQ:VXRT) on Thursday reported new details from a pre-clinical animal study of the company's COVID-19 vaccine candidate. According to the company, there was "significant reduction" of lung viral load in hamsters that received the vaccine, compared to non-vaccinated animals. And there was evidence that it generated a strong immune system response, as the vaccinated animals displayed antibody titers above 10,000....
https://www.fool.com/investing/2020/11/1...gn=article
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
Vaxart, Inc.
Thu, November 12, 2020, 10:01 PM
Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed
Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model
Restarting the Norovirus program
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate update, including updates on its oral COVID-19 vaccine pre-clinical studies and clinical trials....
https://finance.yahoo.com/news/vaxart-re...aYDadwXMOl
The tiny biotech's COVID-19 vaccine has generated excitement because it's a pill instead of a shot, which gives it a number of important advantages.
Nov 12, 2020 at 12:47PM
Vaxart (NASDAQ:VXRT) on Thursday reported new details from a pre-clinical animal study of the company's COVID-19 vaccine candidate. According to the company, there was "significant reduction" of lung viral load in hamsters that received the vaccine, compared to non-vaccinated animals. And there was evidence that it generated a strong immune system response, as the vaccinated animals displayed antibody titers above 10,000....
https://www.fool.com/investing/2020/11/1...gn=article
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
Vaxart, Inc.
Thu, November 12, 2020, 10:01 PM
Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed
Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model
Restarting the Norovirus program
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate update, including updates on its oral COVID-19 vaccine pre-clinical studies and clinical trials....
https://finance.yahoo.com/news/vaxart-re...aYDadwXMOl
__________________
